Ovarian Cancer Drugs Market Pipeline Analysis 2018
Posted by psaraf on September 19th, 2019
Ovarian cancer is one of the most dreadful type of cancer widely found in women. In this cancer, abnormal cells growth is experienced in the ovaries, which has potential to invade or adversely affect other body parts such as abdomen layers, lining of the bowel and bladder, lymph nodes, and liver. Initial stages of ovarian cancer are associated with few vague symptoms, which further manifest as the cancer grows. These symptoms include inflating, pelvic ache, abdominal puffiness, and loss of appetite.
Request A Sample Copy: http://bit.ly/2mk94EF
Ovarian cancer is a relatively rare cancer as compared to other types, though risk is higher among women who have ovulated more over their lifetime, which can also include females who have never borne a child and those who began ovulating at a very young age. According to American Cancer Society, around 10% of ovarian cancer cases are related to inherited genetic risk. Women with mutations in BRCA1 or BRCA2 genes have 50% chance of developing breast or ovarian cancer. Ovarian carcinoma, is the most common ovarian cancer that accounts for 95% of cases, globally.
Ovarian cancer drugs market supported by growing aging population in the U.S. and U.K.
Rising number of ovarian cancer cases recorded over the recent past, is creating a highly conducive environment for growth of the ovarian cancer drugs market. According to American Cancer Society, in 2016, around 22,280 new cases of ovarian cancer were diagnosed, leading to 14,240 deaths in the U.S. According to the Surveillance, Epidemiology and End Results (SEER) Program of the National Cancer Institute data, an increase in all new cancer cases is recorded, with ovarian cancer accounting for 1.3% of the incidence rate, and 2.4% of all related deaths, in 2016. The number of new ovarian cancer cases account for 11.9 per 100,000 women, and the total deaths account for 7.5 per 100,000 women, annually.
According to World Cancer Research Fund International data on the basis of highest rate of ovarian cancer by country: Fiji, age standardized rate per 100,000 is 14.9, followed by Latvia and Bulgaria with age standardized rate per 100,000 being 14.2 and 14.0, respectively. The U.K. stands tenth, with age standardized rate per 100,000 pegged at 11.7. Around 58% of ovarian cancer cases are diagnosed in emerging economies, with the highest incidence rate recorded in Africa and Asia Pacific. In the U.K., around 46% of women diagnosed with ovarian cancer, survive for around five years or more following the onset of the disease. According to Australian Government, Cancer Australia, as of 2017, 1,580 new ovarian cancer cases are estimated to be diagnosed, accounting for 2.5% of ovarian cancer cases among all new cancer cases in the country. This is estimated to result in 1,047 deaths in 2017. Thus, the ovarian cancer drugs industry is expected to gain significant traction in developed regions, in the near future.
Current scenario in ovarian cancer drugs market: High prevalence of ovarian cancer among women over 60 years in the U.S. and U.K.
Regional segmentation of the global ovarian cancer drugs market by Coherent Market Insights comprises North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. North America accounts for the largest market share, mainly due to presence of major players and adoption of advanced medical technologies in countries such as the U.S. and Canada.
According to American Cancer Society, most of the ovarian cancer cases are reported among women aged 60 years and above. According to Cancer Research UK, in 2014, 7,378 new cases of ovarian cancer were reported in the country, of which around 53% of cases diagnosed were among females aged 65 years and above.
Combinational drug approach, a novel approach in the ovarian cancer drugs market
Key players operating in the ovarian cancer drugs market include Bristol Myers Squibb Company, Eli Lilly and Company, GlaxoSmithKline plc, Janssen Pharmaceuticals, Inc., Novogen, Inc., Genentech Inc., Aetera Zenteris Inc., Boehringer Ingelheim GmbH, and F. Hoffman-La Roche Ltd. Major companies in this market are constantly working towards introducing innovative products and lowering production costs in order to enhance profitability. For instance, Roche’s blockbuster drug Avastin (bevacizumab) used in combination with carboplatin and paclitaxel is being used to treat ovarian cancer.
Research and development related to the diagnosis and treatment of ovarian cancer is expected to offer lucrative opportunities for market players. For instance, in August 2019, researchers from The George Washington University School of Medicine and Health Sciences, U.S. identified ovarian cancer drug resistance protein that needs to be blocked for the treatment of patients with platinum-resistant ovarian cancer.
Click To Read More On: Ovarian Cancer Drugs Market
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Coherent Market Insights
1001 4th Ave,
Seattle, WA 98154
Tel: +1-206-701-6702Ovarian Cancer, Cancer Drugs, Cancer Cases, Drugs Market, Women, Ovarian, Market
Binary Options Trading Signals
BOTS room has been around for over 6 years and is the community everyone uses for strategy development for options and Forex. With market veterans with over 20 years experience, what could be better!